**RAPID COMMUNICATION**

**Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma**

Li-Xin Jiang, Jie Xu, Zhao-Wen Wang, Da-Peng Li, Zhi-Hai Peng, Jian-Jun Gao, Lin He, Hai-Tao Zheng

**Abstract**

**AIM:** To search candidate tumor suppressor genes (TSGs) on chromosome 4q through detecting high loss of heterozygosity (LOH) regions in sporadic colorectal carcinoma in Chinese patients.

**METHODS:** Thirteen fluorescent labeled polymorphic microsatellite markers were analyzed in 83 cases of colorectal carcinoma and matched normal tissue DNA by polymerase chain reaction (PCR). PCR products were electrophoresed on an ABI 377 DNA sequencer. Genescan 3.7 and Genotype 3.7 software were used for LOH scanning and analysis. Comparison between LOH frequency and clinicopathological factors were performed by $\chi^2$ test.

**RESULTS:** Data were collected on all informative loci. The average LOH frequency on 4q was 28.56%. The D4S2915 locus showed highest LOH frequency (36.17%). Two obvious deletion regions were detected: one between D4S3000 and D4S2915 locus (4q12-21.1), another flanked by D4S407 and D4S2939 locus (4q25-31.1). None case showed complete deletion of 4q, most cases displayed interstitial deletion pattern solely. Furthermore, compared with clinicopathological features, a significant relationship was observed between LOH frequencies on D4S3018 locus. In tumors larger than 5 cm in diameter, LOH frequency was significantly higher than tumors that were less than 5 cm (56% vs 13.79%, $P = 0.01$). On D4S1534 locus, LOH was significantly associated with liver metastasis (80% vs 17.25%, $P = 0.012$). No relationship was detected on other locus compared with clinicopathological features.

**CONCLUSION:** By high resolution deletion mapping, two high frequency regions of LOH (4q12-21.1 and 4q25-31.1) were detected, which may contribute to locate TSGs on chromosome 4q involved in carcigenesis and progression of sporadic colorectal carcinoma.

© 2008 The WJG Press. All rights reserved.

**Key words:** Loss of heterozygosity; Colorectal carcinoma; Chromosome; 4q; Tumor suppressor gene

**Peer reviewer:** Yoshitomo Motoo, MD, PhD, FACP, FACG, Professor and Chairman, Department of Medical Oncology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan

Jiang LX, Xu J, Wang ZW, Li DP, Peng ZH, Gao JJ, He L, Zheng HT. Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma. *World J Gastroenterol* 2008; 14(36): 5606-5611 Available from: URL: http://www.wjgnet.com/1007-9327/14/5606.asp DOI: http://dx.doi.org/10.3748/wjg.14.5606

**INTRODUCTION**

Colorectal Cancer (CRC) is one of the most common malignant tumors threatening people's health. After lung cancer in men and breast cancer in women, it is the most common cause of cancer related death. Improvement in its prognosis will not be achieved without a better understanding of its etiology and tumor molecular biology. In recent years, the genetic basis of human tumors has been increasingly elucidated. As a modal for both multistep and multipathway carcinogenesis, colorectal neoplastic progression provides paradigms of both oncogenes and tumor suppressor gene (TSG) in epithelial tumors. The latter changes predominate. In addition to the allelic loss noted on chromosome 5q, 17p and 18q, many other chromosome losses can be observed in colorectal
Materials and Methods

Patient sample and DNA extraction

This study was based on eighty-three consecutively collected tumors, including 40 males and 43 females, from unrelated patients with CRC, treated at the Surgical Department in Shanghai First People's Hospital, China. The patients' ages ranged from 31 to 84 years with a median of 66. The cancerous tissue and adjacent normal tissue were fresh frozen. These tissues were cut into cubes of approximately 2 mm^3^ and immediately frozen in liquid nitrogen. DNA was extracted using standard methods with proteinase K digestion and phenol/chloroform purification. All patients were confirmed by pathology, and were staged by Duke's criterion. Each patient gave his or her informed consent for the use of his or her tissue in this study.

Microsatellite markers and polymerase chain reaction (PCR)

Initially, 83 cases of CRC were analyzed by PCR using thirteen microsatellite markers which map to 4q. DNA samples were analyzed as tumor and matched normal pairs using primers of the following microsatellite loci: centromere--D4S3000 (4q12)--D4S3018 (4q13.3)--D4S1535 (4q13.2)--D4S2915 (4q21.1)--D4S1534 (4q21.23)--D4S2986 (4q22.1)--D4S407 (4q22.23)--D4S2962 (4q23.2)--D4S3046 (4q31.2)--D4S3045 (4q31.3)--D4S3018 (4q32.1)--D4S3046 (4q32.2)--D4S430 (4q34.1)--D4S3018 (4q34.3)--D4S1535 (4q35.1)--D4S1534 (4q35.2). None case showed complete deletion of 4q, frequent allelic loss were observed on chromosome 4q, the average LOH frequency on 4q was 28.56%. Seventy-two samples (86.75%) showed LOH informative messenger (Table 1). Tumors exhibiting wide microsatellite instability were excluded from deletion mapping. The average LOH frequency of 4q was 28.56%. Seventy-two samples (86.75%) showed LOH

Statistical analysis

Date was statistically analyzed using the SPSS software package, version 11.5 (SPSS Inc). Comparisons between LOH and clinicopathological data were performed by χ^2^-test. P < 0.05 was considered as statistically significant.

Results

LOH analysis of CRC on 4q

Eighty-three CRCs were analyzed for LOH at thirteen marker loci spanning chromosome 4q. All loci got informative messenger (Table 1). Tumors exhibiting wide microsatellite instability were excluded from deletion mapping. The average LOH frequency of 4q was 28.56%. Seventy-two samples (86.75%) showed LOH event on at least one locus. The D4S2915 locus showed highest LOH frequency (36.17%). Two distinct region of frequent allelic loss were observed on chromosome 4q, one between D4S3000 and D4S2915 locus (4q12-21.1), another flanked by D4S407 and D4S2939 locus (4q25-31.1). None case showed complete deletion of 4q,
most cases displayed interstitial deletion pattern solely. It can be speculated that putative TSGs may locate on 4q12-21.1 and 4q25-31.1.

**Relationship between clinicopathological features and LOH on 4q**

Compared with clinicopathological features, by statistics, a significant relationship was observed between LOH frequency on D4S3018 and tumor diameter. LOH frequency in tumors larger than 5 cm in diameter (50%, 14/25) was significantly higher than tumors that were less than 5 cm in diameter (13.79%, 4/29; P = 0.01). On 4S1534 locus, LOH frequency was 80% (4/5) in cases with liver metastasis, which was significantly higher than that without liver metastasis (17.25%, 5/29) (P = 0.012). No relationship was detected on other locus compared with these clinicopathological features.

**DISCUSSION**

Inactivation of TSGs appears to be one of the genetic mechanisms involved in the development of CRC[3,11,12]. Deletion of TSGs occurs frequently in human malignancies. Such events can be detected using markers from the region of genomes that include a TSG. Allelic loss detected as LOH have been proved useful for mapping regions of DNA that contain TSGs. LOH at specific chromosomal regions strongly suggests the existence of TSGs at the relevant segment.

Studies conducted thus far have focused on known TSG, particularly, APC, p53, DCC, MCC, Smad4 and so on. The genetic events that led to the development and progression of CRC on chromosome 4q have not been elucidated. There were a lot of evidence that multiple genetic abnormalities on 4q contribute to development of a serials of tumors, and that supported the presence of TSGs in the long arm of chromosome 4.

Loss of chromosome 4q has been found in the majority of breast carcinoma[13], cervical cancer (4q21-q25)[14]. In oral squamous cell carcinoma[15] and relapsed childhood acute lymphoblastic leukemia[16], 75% and 20% cases showed LOH on at least one of the loci, with frequent loss region centered on 4q25 in the former. In esophageal adenocarcinoma, Hammond et al[17] found LOH frequency was 54.5%-65% on 4q21-35 with a lower resolution allelotyping studying. Rumpel et al[18] found LOH was 80% on at least one marker on 4q, and discerned three non-overlapping areas (4q21.1-22, 4q32.2-33, 4q35), whose total spanning length is quite coincident with Hammond[17]. Hurst et al[19] found that in bladder cancer, 4q loss was the most frequent loss (83%) in all arms of chromosome by microarray-based comparative genome hybridization, with the minimal region of deletion at 4q13.1 and 4q31.3. This result was compatible with previous report of LOH analysis in bladder tumors[20]. In malignant mesothelioma and small cell lung cancer, two non-overlapping loss region on 4q were at 4q33-34 (>80%) and 4q25-26 (>60%)[21]. In primary small cell lung cancer, Cho et al[22] defined five commonly deleted region all more than 50% on 4q, namely, 4q24, 4q27-28.3, 4q33, 4q34.1 and 4q34.3-35.2. In the research of hepatocellular carcinoma, much work has been done. Piao et al[23] made a detailed deletion mapping and identified seven independent, frequently lost regions. In fact, a high frequency of LOH on chromosome 4q in hepatocellular carcinoma has been reported by several study groups[24-27]. Recent years, LOH frequency was found 33.3% (at 4q26-27)[28], 50%[29], and 38%[30] for at least two adjacent markers in hepatocellular carcinoma. These study results strongly suggested that 4q may locate more than one putative TSG.

The research of LOH on 4q in colorectal carcinoma was much less in this decade. LOH at telomere markers have been reported less than 10% on 4q[31]. Analysis of

**Table 1  LOH frequency statistics result on 4q**

| Marker    | Location | LOH Normal case | LOH Informative case | Distance (cm) | LOH rate |
|-----------|----------|-----------------|----------------------|---------------|----------|
| D4S3000   | 4q12     | 22              | 42                   | 78.05         | -        | 34.38    |
| D4S3018   | 4q13.2   | 18              | 36                   | 56.05         | 9.7      | 33.33    |
| D4S3015   | 4q21.1   | 17              | 30                   | 56.63         | 10.6     | 36.17    |
| D4S3034   | 4q21.23  | 9               | 25                   | 40.96         | 7.5      | 26.47    |
| D4S3086   | 4q23     | 7               | 39                   | 55.42         | 10.6     | 15.22    |
| D4S407    | 4q25     | 17              | 35                   | 62.56         | 10.7     | 32.69    |
| D4S300    | 4q28.1   | 15              | 35                   | 60.24         | 11.1     | 30       |
| D4S3093   | 4q31.1   | 21              | 38                   | 71.08         | 14.4     | 35.59    |
| D4S3062   | 4q31.23  | 16              | 43                   | 71.08         | 12.1     | 27.12    |
| D4S3046   | 4q32.2   | 16              | 39                   | 66.27         | 13.3     | 29.09    |
| D4S3079   | 4q32.3   | 7               | 25                   | 36.78         | 12.6     | 21.87    |
| D4S3145   | 4q34.3   | 14              | 36                   | 60.24         | 6.6      | 28       |
| D4S3155   | 4q35.1   | 14              | 45                   | 71.08         | 14       | 23.73    |
mid-position microsatellite markers on 4q arm showed moderate of allelic imbalances (< 25%) in colorectal tumors[39]. Comparative genomic hybridization analysis of a serial of colorectal adenomas and carcinomas identified chromosome 4 losses as of the recurrent alterations observed in malignant stages[33]. Arribas et al[36] found frequent loss on 4q21-28 in CRC by using AP-PCR method. However, detailed mapping of the long arm of chromosome 4 has not been reported in colorectal carcinoma thus far.

With high resolution markers, we performed detailed LOH analysis and observed two obvious deletion regions: one between D4S3000 and D4S2905 locus (4q12-21.1), another flanked by D4S407 and D4S2939 locus (4q25-31.1). The first region included 4q12-21.1, 4q13.1[33], furthermore, the region was adjacent with 4q21-25[14], 4q21-35[17], 4q21.1-22[19], 4q33-34[23] detected before. The second region was adjacent with 4q21-25[14], 4q25[15], 4q31.3[19], covered by 4q21-35[17], and completely spanned 4q32-33[18], 4q25-26[23], 4q27-28.3, 4q33[23], 4q26-27[28] partially overlapped with 4q21-28[14], 4q24-26[19] as well. Because of different LOH judge criteria and different density markers used, the minimal deletion region in different tumors displayed discrepancy.

LOH on chromosome 4q seems to be correlated with aggression features and a late genetic event involved with the progression rather than the initiation of cancer. In hepatocellular carcinoma, a study by Okabe et al[58] showed that the high rate of LOH on 4q are associated with a poor differentiation of tumors, vascular invasion and intrahepatic metastasis in hepatocellular carcinoma. A similar finding was made by Konishi et al[37], LOH was found in 71% of poorly differentiated hepatocellular carcinoma. Rashid et al[29] found 4q was preferentially lost in hepatocellular carcinoma containing p53 mutation, that is, LOH of 4q was present in 75% of hepatocellular carcinoma with, but only 25% of hepatocellular carcinoma without a p53 gene mutation (P = 0.01), indicating a possible interaction between p53 gene mutation and 4q loss in the pathogenesis of hepatocellular carcinoma. Loss of 4q34-35 regions showed a significant association with alcohol intake (P = 0.05) and with high grade of differentiation (P = 0.02) in hepatocellular carcinoma[9]. Investigators[22] thought TSG on 4q play an important role in pathogenesis of malignant mesothelioma and small cell lung cancer, because non-small cell lung cancer had lower frequency at this region. Similarly, the result of primary bladder cancer correlated allelic loss with advanced tumor stage and grade of the lesions[18]. Piao et al[29] found five regions among seven common deleted regions was associated with tumor differentiation, suggesting that allelic loss on chromosome 4q is a late genetic event involved in the progression rather than in the initiation of hepatocarcinogenesis. Pershouse et al[38] reported that the allelic deletion involving 4q may represent an early event in head and neck squamous cell carcinoma oncogenesis.

A significant relationship was detected between LOH frequency on D4S3018 and tumor diameter. LOH frequency in tumors larger than 5 cm was significantly higher than tumors less than 5 cm in diameter (P = 0.01). On D4S1534 locus, LOH rate was significantly associated with liver metastasis (P = 0.012). It can be speculated that these events were associated with progression after tumorigenesis, indicating a late event in colorectal carcinoma.

No statistical significant correlation was found between the presence of LOH and clinicopathological data in oral squamous cell cancer[13], esophageal adenocarcinoma[37] and in Taiwanese hepatocellular carcinoma[26].

By scanning GeneMap’ 99 database, and searching www.gdb.org, four genes should be studied further. PTPN13 (4q21.3) is a Fas-associated protein, tyrosine phosphate that binds to a negative regulatory domain in the FAS protein and inhibits Fas-induced apoptosis[39]. Caspase3 (4q34) and caspase6 (4q24-35), mammalian homologues of Ced-3 gene, are responsible for cleavage and inactivation of key homeostatic protein during apoptosis[39]. T1A12/mac25 (4q12-13) expression is abrogated during breast cancer progression concomitant with LOH on chromosome 4q, indicating its tumor suppressor function[40]. All of these three genes are putative TSGs.

In summary, this is the first detailed LOH analysis on chromosome 4q in CRC by using high resolution microsatellite markers. We detected two non-overlapping deletion region (4q12-21.1 and 4q25-31.1), which may contain TSGs. Additional attempts will aide in the discovery of the genes inactivated by these deletion events. The elucidation of the biochemical property of these gene products will be an important step in understanding the biology of this highly lethal and common cancer.

**COMMENTS**

**Background**

Cancer arises from the accumulation of inherited polymorphism (i.e. SNPs) and mutation and/or sporadic somatic polymorphism (i.e. non-germline polymorphism) in cell cycle, DNA repair, and growth signaling genes. Neoplastic progression is generally characterized by the accumulation of multiple somatic-cell genetic alterations as the tumor progresses to advanced stages. The classic mechanism of tumor suppressor gene (TSG) inactivation is described by two-hit modes in which one allele is mutated (or promoter hypermethylation or a small intragenic deletion) and the other allele is lost through a number of possible mechanisms, resulting in loss of heterozygosity (LOH) at multiple loci. LOH is the most common molecular genetic alteration observed in human cancers. In the model of colorectal tumorigenesis, mutational inactivation of TSGs predominates.

**Research frontiers**

Most genome-wide scans for LOH have been conducted at low resolution with a relatively small number of polymorphic markers. For example, an average of 120 microsatellites have been used to determine the allelotype of multiple different human neoplasms in a series of studies since 1995, and the highest density microsatellite allelotype was approximately 280 polymorphic markers before the year 2000. SNPs are the most common form of sequence variation in human genome, occurring approximately every 1200 bp. High density mapping of genetic losses reveals potential tumor suppressor loci and might be useful for clinical classification of individual tumors. SNP array has been introduced recently for genome-wide screening of chromosome imbalance. Higher density SNP array can effectively detect small regions of chromosomal changes and provide more information regarding the boundaries of loss regions.
Innovations and breakthroughs
A great deal of evidence supported the presence of TSGs in the short arm of chromosome 4. Fewer studies have been reported in colorectal cancer. Previous allelotyping analysis of cancer by many groups was used with a relatively low density of markers. By deletion dense markers mapping, authors detected two obvious high frequency LOH regions spanning D4S3013 and D4S405 locus in colorectal cancer (CRC). Candidate TSG might be located between D4S3017 and D4S2933 (about 1.7 cm).

Applications
This method could be used to detect some major allelic loss regions in genome-wide scans of LOH in patients with CRC.

Terminology
LOH is caused by a variety of genetic mechanisms, including physical deletion of chromosome non-disjunction and mitotic non-disjunction followed by repopulation of the remaining chromosomes, mitotic recombination and gene conversion. The mechanisms of LOH are remarkably chromosome-specific. Some chromosomes display a complete loss. However, more than half of the losses are associated with only a partial loss of a chromosome rather than a whole chromosome. LOH is also a common form of allelic imbalance and the detection of LOH has been used to identify genomic regions that harbor TSGs and to characterize different tumor types, pathological stages and progression.

Peer review
This is a report that describes the LOH events on 4q in sporadic CRC in Chinese patients, further studies will benefit from this paper. The data presented is clear and concise in the text.

REFERENCES
1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafour A, Feuer EJ, Thun MJ. Cancer statistics. 2005. CA Cancer J Clin 2005; 55: 10-30
2. Heitman SJ, Mammas BJ, Hiltsden RJ, Fong A, Dean S, Romagnuolo J. Cost-effectiveness of computerized tomographic colonography versus colonoscopy for colorectal cancer screening. CMAJ 2005; 173: 877-881
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
4. Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer. Molecular basis for risk factors. BMJ 2000; 321: 886-889
5. Kataoka M, Okahayashi T, Johira H, Nakatani S, Nakashima A, Takeda A, Nishizaki M, Orita K, Tanaka N. Aberration of p53 and DCC in gastric and colorectal cancer. Oncol Rep 2000; 7: 99-103
6. Lenguager C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649
7. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-221
8. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991; 251: 1366-1370
9. Xu SF, Peng ZH, Li DP, Qiu GQ, Zhang F. Refinement of heterozygosity loss on chromosome 5p15 in sporadic colorectal cancer. World J Gastroenterol 2003; 9: 1713-1718
10. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gysay P, Morissette J, Weissbench J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 1996; 380: 152-154
11. Hinoi T, Akyol A, Theisen BK, Ferguson DO, Green KN, Williams BO, Cho KR, Fearon ER. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007; 67: 9711-9730
12. Komarova NL, Lengauer C, Vogelstein B, Nowak MA. Dynamics of genetic instability in sporadic and familial colorectal cancer. Cancer Biol Ther 2002; 1: 685-692
13. Schwendel A, Richard F, Langreck H, Kaufmann O, Lage H, Winzer KJ, Petersen I, Dietel M. Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br J Cancer 1998; 78: 806-811
14. Mitra AB, Murty VV, Li RG, Pratap M, Luthra UK, Chaganti RS. Allelotype analysis of cervical carcinoma. Cancer Res 1994; 54: 4481-4487
15. Wang XL, Uzawa K, Imai FL, Tanzawa H. Localization of a novel tumor suppressor gene associated with human oral cancer on chromosome 4q25. Oncogene 1999; 18: 823-825
16. Takeuchi S, Seriu T, van Dongen JJ, Szczepanski T, Tsukasaki K, Takeuchi N, Fermin AC, Seo H, Bartram CR, Koelle HF. Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene 2003; 22: 6970-6976
17. Hammoud ZT, Kaleem Z, Cooper JD, Sundaresan RS, Patterson GA, Goodfellow PJ. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996; 56: 4499-4502
18. Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 1999; 154: 1329-1334
19. Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004; 23: 2250-2263
20. Polascik TJ, Cairns P, Chang WY, Schoenberg MP, Sidransky D. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 1995; 55: 5396-5399
21. Rosin MP, Cairns P, Epstein JJ, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res 1995; 55: 5213-5216
22. Shivaipurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, Gazdar AF. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 1999; 5: 17-23
23. Cho ES, Chang J, Chung KY, Shin DH, Kim YS, Kim SK, Kim SK. Identification of tumor suppressor loci on the long arm of chromosome 4 in primary small cell lung cancers. Yonsei Med J 2002; 43: 145-151
24. Piao Z, Park C, Park JH, Kim H. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer 1998; 79: 356-360
25. Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsuobu M, Ishikawa T, Nakagama H, Harada H. Allelotype study of primary hepatocellular carcinoma. Cancer Res 1991; 51: 89-93
26. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997; 14: 2927-2933
27. Tsuda H, Zhang WD, Shimosato Y, Yokota J, Terada M, Sugimura T, Miyamura T, Hirohashi S. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6791-6794
28. Chou YH, Chung KC, Jeng LB, Chen TC, Liaw YF. Frequent allelic loss on chromosomes 4q and 16q associated with human bladder cancer. Urology 1995; 46: 21-26
29. Rashid A, Wang JS, Qian GS, Lu BX, Hamilton SR, Groopman JD. Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. Br J Cancer 1999; 80: 59-66
30. Bluteau O, Beaudoin JC, Pasturaud P, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J. Specific association between alcohol intake, high grade of differentiation and 4q34-p35 deletions in hepatocellular carcinomas identified by high resolution allelotyping.
31 Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science 1989; 244: 207-211
32 Thorstensen L, Qvist H, Nesland JM, Giercksky KE, Lothe RA. Allelotype profiles of local recurrences and distant metastases from colorectal-cancer patients. Int J Cancer 1996; 69: 452-456
33 Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, Heselmeyer K, du Manoir S, Auer G. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 1996; 15: 234-245
34 Arribas R, Risques RA, Gonzalez-Garcia I, Masramon L, Aiza G, Ribas M, Capella G, Peinado MA. Tracking recurrent quantitative genomic alterations in colorectal cancer: allelic losses in chromosome 4 correlate with tumor aggressiveness. Lab Invest 1999; 79: 111-122
35 Pershouse MA, El-Naggar AK, Hurr K, Lin H, Yung WK, Steck PA. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene 1997; 14: 369-373
36 Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, Katsura N, Nishitai R, Takeyama O, Fukumoto M, Yamaoka Y. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology 2000; 31: 1073-1079
37 Konishi M, Kikuchi-Yanoshita R, Tanaka K, Sato C, Tsuru K, Maeda Y, Koike M, Tanaka S, Nakamura Y, Hattori N. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn J Cancer Res 1993; 84: 893-899
38 Inazawa J, Ariyama T, Abe T, Druck T, Ohta M, Huebner K, Yanagisawa J, Reed JC, Sato T. PTPN13, a fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3. Genomics 1996; 31: 240-242
39 Nasir J, Theilmann JL, Chopra V, Jones AM, Walker D, Rasper DM, Vaillancourt JP, Hewitt JE, Nicholson DW, Hayden MR. Localization of the cell death genes CPP32 and Mch-2 to human chromosome 4q. Mamm Genome 1997; 8: 56-59
40 Burger AM, Zhang X, Li H, Ostrowski JL, Beatty B, Venanzoni M, Papas T, Seth A. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998; 16: 2459-2467

S-Editor Li DL  L-Editor Alpini GD  E-Editor Zhang WB